Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
China Resources Jinchan Pharmaceutical, a subsidiary of China Resources Sanjiu, is a prominent Chinese pharmaceutical company specializing in the development and manufacture of Traditional Chinese Medicine (TCM) for oncology. The company is best known for its flagship product, Huachansu (Cinobufacini), which is derived from toad venom and used extensively in China for treating various malignancies, including liver and lung cancers. Based in Huaibei, Anhui Province, the company operates modern GMP-certified manufacturing facilities and maintains a strong focus on the modernization of TCM. Its portfolio includes injections, capsules, and tablets aimed at improving the quality of life and survival rates for cancer patients. As part of the larger China Resources Group, it benefits from an extensive domestic distribution network and significant R&D resources.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on China Resources Jinchan Pharmaceutical.